Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI) was the target of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 3,870,000 shares, a decline of 17.0% from the December 15th total of 4,660,000 shares. Based on an average daily volume of 1,690,000 shares, the short-interest ratio is currently 2.3 days.

Trevi Therapeutics Trading Down 0.5 %

NASDAQ TRVI traded down $0.02 on Friday, hitting $3.76. The company’s stock had a trading volume of 258,536 shares, compared to its average volume of 1,018,180. The firm has a market cap of $289.03 million, a P/E ratio of -8.55 and a beta of 0.87. Trevi Therapeutics has a 52-week low of $1.27 and a 52-week high of $4.68. The company’s 50-day simple moving average is $3.50 and its 200 day simple moving average is $3.18.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter in the prior year, the company posted ($0.08) earnings per share. On average, research analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. B. Riley restated a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a research report on Monday, October 7th. HC Wainwright increased their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a report on Thursday, December 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, January 8th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Trevi Therapeutics currently has an average rating of “Buy” and an average target price of $9.31.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its stake in Trevi Therapeutics by 38.8% in the second quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company’s stock worth $532,000 after buying an additional 49,884 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Trevi Therapeutics by 44.8% during the 2nd quarter. Rhumbline Advisers now owns 75,218 shares of the company’s stock worth $224,000 after acquiring an additional 23,263 shares during the period. American Century Companies Inc. raised its position in shares of Trevi Therapeutics by 17.1% in the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock worth $161,000 after acquiring an additional 7,902 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Trevi Therapeutics by 217.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 72,210 shares of the company’s stock valued at $215,000 after purchasing an additional 49,475 shares during the period. Finally, Hsbc Holdings PLC purchased a new position in shares of Trevi Therapeutics in the 2nd quarter valued at approximately $61,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.